Quince Therapeutics (NASDAQ:QNCX) Stock Rating Raised to “Strong-Buy” at Rodman & Renshaw

Rodman & Renshaw upgraded shares of Quince Therapeutics (NASDAQ:QNCX) to a strong-buy rating in a report released on Thursday,Zacks reports.

Other equities research analysts also recently issued research reports about the stock. Lifesci Capital upgraded shares of Quince Therapeutics to a “strong-buy” rating in a research note on Monday, June 29th. Weiss Ratings downgraded Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 26th. Zacks Research raised Quince Therapeutics to a “hold” rating in a report on Wednesday, June 24th. Oppenheimer initiated coverage on Quince Therapeutics in a research report on Wednesday, July 29th. They set an “outperform” rating and a $82.00 target price for the company. Finally, Craig Hallum upgraded Quince Therapeutics to a “strong-buy” rating in a research report on Thursday, August 27th. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $206.71.

Quince Therapeutics Trading Down 0.5%

Quince Therapeutics stock opened at $30.00 on Thursday. The firm’s fifty day simple moving average is $28.41 and its 200-day simple moving average is $23.97. Quince Therapeutics has a 1-year low of $15.10 and a 1-year high of $909.98. The company has a market capitalization of $30.60 million, a P/E ratio of -0.19 and a beta of 1.31.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings results on Friday, August 14th. The company reported ($12.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($28.02) by $15.71.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in Quince Therapeutics in the 2nd quarter worth approximately $31,000. 683 Capital Management LLC acquired a new stake in shares of Quince Therapeutics in the 4th quarter valued at $798,000. Finally, Intellectus Partners LLC bought a new stake in shares of Quince Therapeutics during the fourth quarter worth $179,000. Institutional investors and hedge funds own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for rare diseases. The company’s research centers on its erythrocyte-derived extracellular vesicle (EEV) platform, which uses patients’ red blood cells to encapsulate and deliver therapeutic compounds.

Quince’s lead investigational product is eDSP, formerly known as EryDex, an autologous red-blood-cell-based formulation of dexamethasone sodium phosphate being developed for ataxia-telangiectasia (A-T).